Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina

American Journal of Ophthalmology Case Reports

David H. Abramson¹  Julia Canestraro²  Christopher A. Barker³  Jasmine H. Francis³  Alexander N. Shoushtari³ 

[1] Corresponding author. Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.;Weill Cornell Medical Center, New York, NY, USA;Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

关键词: Melphalan;    Metastatic melanoma;    Bevacizumab;    Neovascularization;    Vitreous;    Retina;   

DOI  :  

来源: DOAJ

【 摘 要 】

Purpose: Cutaneous melanoma metastatic to the vitreous/retina is rare but increasingly common. Due to the potential of recurrent disease with current treatment options and the propensity for these eyes to develop neovascularization, these eyes can pose a treatment challenge and novel management strategies are needed. This case series explores the use of combination, sequential intravitreous melphalan and bevacizumab. Observation: Two eyes of two patients with cutaneous melanoma metastatic to the vitreoretina were eye treated with combination intravitreous melphalan (10-30 mcg) and bevacizumab (1.25 mg) given sequentially during the same office visit, at monthly intervals. Both cases had control of disease at 7- and 12-months follow up. Furthermore, treatment reversed neovascular glaucoma and dramatically improved vision in the eye of one patient; and stabilized vision without the development of neovascularization in the eye of the other patient. There were no ocular adverse events noted in either eye. Conclusions and Importance: Combination, sequential intravitreous melphalan and bevacizumab is well-tolerated and an attractive approach for treating eyes with intraocular metastatic melanoma.

【 授权许可】

Unknown